Nicotine Buccal Pouches in Canada: Health Canada’s Amendment Clarifies Prescription vs. Non Prescription Status

---

---

Health Canada has officially updated the Prescription Drug List to clarify the non prescription status of nicotine buccal pouches containing 4 milligrams of nicotine or less per dosage unit. This change provides long awaited clarity for manufacturers, importers, and retailers entering the rapidly growing nicotine pouch category.

The amendment, effective January 14, 2026, introduces a new qualifier specific to nicotine buccal pouches and separates them from sprays and inhalers. This ensures that low dose pouches are recognized as non prescription Natural Health Products (NHPs) regulated under the Natural Health Products Regulations.

This update follows Health Canadas earlier consultation and aligns nicotine pouches with other established Nicotine Replacement Therapy (NRT) formats already available over the counter.

What Changed in the Prescription Drug List

The Prescription Drug List previously relied on a single qualifier, part “d,” to group all non active buccal delivery devices together. This meant that buccal pouches, sprays, and inhalers were treated under one broad exemption as long as they delivered 4 milligrams or less of nicotine per dose. While this approach worked in practice, it did not reflect the differences between these dosage forms or the recently growing presence of nicotine pouches in the Canadian market.

To address this, Health Canada introduced clearer distinctions so that each format is classified more accurately and with less reliance on interpretation.

Key Updates Include

The first set of changes focuses on restructuring the qualifiers to recognize nicotine buccal pouches directly. Before this amendment, pouches were indirectly captured through a general reference to non active buccal devices. By separating nicotine pouches from sprays and inhalers, Health Canada has eliminated ambiguity and strengthened regulatory consistency. The following changes were introduced:

These updates set the foundation for a cleaner, more intuitive structure that better reflects how these products are used and regulated.

Introduced Clarifications

With these amendments in place, the classification framework is now easier to interpret and apply. The new structure provides a clear boundary between non prescription and prescription nicotine pouches, ensuring consistent oversight across all manufacturers and product types.

The new structure makes it clear and reinforces the following:

This clarity strengthens regulatory predictability and helps sponsors confidently prepare formulations, licensing submissions, and market strategies that align with Health Canadas expectations.

Why This Amendment Matters

Nicotine pouches represent one of the newest NRT formats available to adult smokers seeking a discreet, smoke free option for smoking cessation. These products deliver nicotine through buccal absorption, without inhalation, combustion, or vapour production. Each pouch contains nicotine and non-medicinal ingredients, such as flavours, enclosed in a small sachet placed between the gum and cheek. Health Canadas earlier consultations noted a growing interest in these formats, but also highlighted the need for clearer regulatory alignment as the category expanded.

The updated qualifier formally recognizes nicotine pouches within the same regulatory framework used for other low dose NRT formats. When a pouch contains 4 milligrams or less of nicotine per dosage unit, it is treated consistently with gums, lozenges, patches, and other non prescription cessation aids.

Clearer Alignment with NRT Expectations

This amendment brings nicotine pouches into direct alignment with Health Canadas long standing approach to over the counter NRTs. Previous guidance on smoking cessation products has consistently emphasized dose limits, suitability for self selection, and safe use without practitioner supervision. By explicitly naming nicotine pouches, Health Canada confirms that low dose pouch formats meet these criteria and fall within the established non prescription NRT category.

Removal of Regulatory Ambiguity

Before this update, manufacturers relied on interpretation to determine whether nicotine pouches were captured under part “d” of the qualifier as non-active buccal devices. The lack of explicit wording created room for uncertainty, especially as new formulations and pouch styles entered the market. The amended qualifier removes this ambiguity and provides a direct reference point that can be cited during licensing, compliance reviews, and internal regulatory planning.

Consistent application of Canadian legislation

With nicotine pouches now clearly identified, sponsors can apply the Food and Drugs Act, the Natural Health Products Regulations, and the Food and Drug Regulations with greater precision. This supports consistent classification across all NRT formats and reduces the risk of misinterpretation or inconsistent market practices, which Health Canada flagged as a concern during its earlier consultations.

Stronger Product Planning and Market Readiness

For industry, this clarity translates into practical advantages. Sponsors can confidently design formulations that meet the 4 milligram threshold for non prescription status, prepare Product Licence Applications (PLAs) that reflect Health Canadas expectations, and develop compliant labelling and claims aligned with NRT requirements. This regulatory certainty supports smoother product development, more predictable review timelines, and stronger planning for Canadian market entry.

Regulatory Status of Nicotine Pouches: NHP vs Prescription Drug

The clarified distinction determines not only whether a product is prescription or non prescription, but also which regulatory pathway applies from a licensing, evidence, and compliance standpoint.

Nicotine Buccal Pouches Regulated as Natural Health Products (NHPs)

Nicotine buccal pouches containing 4 milligrams or less of nicotine per dosage unit are regulated as NHPs under the Natural Health Products Regulations and require an approved Natural Product Number (NPN) prior to market entry. All nicotine containing NHPs, including buccal pouches, must proceed through the Class III licensing pathway, which reflects Health Canada’s evidence expectations for products used in smoking cessation.

Applications for Nicotine Buccal Pouches as NHPs

Under the Class III pathway, applicants must provide a comprehensive evidence package that substantiates the product’s safety, efficacy, quality, and intended conditions of use. For nicotine buccal pouches, this includes data demonstrating buccal absorption and characterizing the delivery kinetics and bioavailability of nicotine in this format. Applicants must also justify the proposed indication, target population, duration of use, and directions for use, with supporting evidence that aligns with Health Canada’s expectations for smoking cessation products.

In addition to the general NHP requirements, oral cavity NRTs such as pouches and pearls are also subject to the Supplementary Rules Respecting Nicotine Replacement Therapies, which introduce enhanced controls related to labelling, packaging, flavour restrictions, mockup submissions, points of sale, and marketing practices. These requirements are intended to reduce the appeal and accessibility of nicotine products among individuals under 18 while maintaining access for adults who rely on NRTs for smoking cessation.

Class III applications undergo an extensive technical review by Health Canada, with a target review timeline of approximately 310 days from the application’s acknowledgement date.

Nicotine Buccal Pouches Regulated as Prescription Drugs

Nicotine buccal pouches containing more than 4 milligrams of nicotine per dosage unit fall under the Food and Drug Regulations and are classified as prescription drugs. Products in this category are governed by the prescription drug framework, which is intended for active ingredients and dosage formats that require greater oversight due to higher exposure, greater potential for dependence, or the need for professional monitoring to support safe use.

Applications for Nicotine Buccal Pouches as Prescription Drugs

At the prescription drug level, applicants should prepare a broader and more detailed evidentiary package than what is required for non prescription products. Submissions must align with the drug review requirements under the Food and Drug Regulations and typically include:

These products may also require evidence or justification related to patient selection, monitoring considerations, and the overall benefit risk profile, as Health Canada evaluates whether professional supervision is necessary for safe and effective use.

Nicotine buccal pouches that exceed the 4 milligram threshold cannot be sold as NHPs and must be dispensed under the controls applicable to prescription drugs in Canada. This ensures that higher strength nicotine products are made available in a manner consistent with Health Canada’s expectations for practitioner oversight and appropriate use.

Takeaways of the Amendment

The most important next steps focus on preparing the right submission package for the product’s classification and ensuring the evidence and documentation are aligned from the outset.

Key Takeaways for Non Prescription Nicotine Buccal Pouches

For products at 4 milligrams or less, applicants should:

Key Takeaways for Prescription Strength Buccal Pouches

Focusing on the correct pathway early helps ensure predictable review timelines and reduces the likelihood of deficiencies or rework during assessment.

Final Remarks

Health Canada’s amendment to the Prescription Drug List represents a meaningful step forward for the nicotine pouch category. By explicitly distinguishing between low dose and prescription strength products, the updated framework removes long standing ambiguity and strengthens regulatory predictability for all stakeholders entering the Canadian market.

Manufacturers and importers now have a clear, structured pathway to follow, whether they are preparing a Class III NHP application or pursuing authorization under the prescription drug framework. This clarity supports better strategic planning, more efficient submissions, and more consistent oversight as the nicotine pouch market continues to grow in Canada.

FAQ

Do existing nicotine pouch products need to take action because of the 2026 PDL amendment?

No immediate action is required solely as a result of the Prescription Drug List amendment if a product was already correctly classified and authorized. The amendment clarifies classification rather than changing it. However, licence holders should confirm that their product strength, dosage form, and labelling remain aligned with the clarified framework and with other applicable NRT requirements.

Does the amendment change the transition timelines under the NRT Supplementary Rules?

No. The PDL amendment does not alter the transition periods established under the Supplementary Rules Respecting Nicotine Replacement Therapies. Those timelines are governed separately and continue to apply to labelling, packaging, marketing, and point-of-sale requirements for oral cavity NRTs.

Can nicotine buccal pouches be sold by self-selection in Canada?

Currently, nicotine buccal pouches regulated as NHPs are subject to additional point-of-sale restrictions under the NRT Supplementary Rules. These products are not included on the list of NRT dosage forms permitted for consumer self-selection and must be sold behind the counter by a pharmacist or under pharmacist supervision, including for online sales.

Are there advertising restrictions for nicotine buccal pouches?

Yes. Advertising and promotion of nicotine buccal pouches must not appeal to young people and must clearly indicate that the product is intended for adults 18 years and older. Required nicotine addiction warnings must be displayed consistently across labels, packaging, and all forms of advertising, including digital and audio formats.

Are flavour options for nicotine pouches restricted?

Yes. Under the NRT Supplementary Rules, flavour options are tightly controlled. Only mint, menthol, or combinations of the two are permitted. Flavours associated with desserts, confectionery, beverages, or energy drinks are prohibited, and flavour descriptors that could appeal to youth or mislead consumers are not allowed.

---

✷ The content on this website, including information presented in this post, is provided for general informational purposes only and does not constitute legal, regulatory, or professional advice. While efforts are made to ensure accuracy, laws and regulations vary by jurisdiction and may change over time. Readers should not rely on this information as a substitute for advice from qualified legal or regulatory professionals. We disclaim any liability for actions taken based on this content, and users are encouraged to seek guidance specific to their circumstances.